MedTrace Logo

Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy

NCT03403699 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-01-22

No results posted yet for this study

Summary

This study proposes to carefully examine the hypothesis that human inducible pluripotent stem cells (iPSCs) can be effectively employed as a future therapeutic option for individuals with diabetic retinopathy and macular ischemia. iPSCs will be generated from the peripheral blood cells of subjects with diabetes and age matched controls. The human iPSC cells will be used to generate mesoderm cells for injection into the vitreous cavity of diabetic rodents and primate eyes. The ability of mesoderm cells to generate endothelial cells and pericytes in areas of degenerated capillaries will be examined. The human iPSCs will also be used to generate hematopoietic CD34+CD45+ cells. The combination of CD34+CD45+ cells derived from iPSCs and iPSC derived mesoderm will be examined in combination for their potentially beneficial effect to enhance the vessel formation.

Conditions

Interventions

BIOLOGICAL

Generation of inducible pluripotent stem cells

Generation of inducible pluripotent stem cells from peripheral blood cells.

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Maria B Grant, MD · 1954

Eligibility

Min Age
21 Years
Max Age
98 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-11
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03403699 on ClinicalTrials.gov